Form 4: Natera Executive Chairman Sells NTRA Shares

Matthew Rabinowitz, Natera's Executive Chairman, reported sales of common stock totaling 49,990 shares across multiple transactions in September 2025, executed under Rule 10b5-1 trading plans.

Summary

• Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NTRA), reported the sale of 49,990 shares of common stock.
• The sales occurred on September 18, 2025, and September 19, 2025.
• A sale of 10,000 shares on September 18, 2025, was executed at a price of $180.00 per share, pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2025.
• An additional 14,473 shares were sold on September 18, 2025, at a weighted average price of $180.1333 per share (ranging from $180.00 to $180.37), under a Rule 10b5-1 trading plan adopted on March 14, 2025.
• On September 19, 2025, 24,339 shares were sold at a weighted average price of $180.543 per share (ranging from $180.00 to $180.99), also under the March 14, 2025, Rule 10b5-1 plan.
• Another 1,188 shares were sold on September 19, 2025, at a weighted average price of $181.282 per share (ranging from $181.00 to $181.40), under the same March 14, 2025, Rule 10b5-1 plan.
• Following these transactions, Matthew Rabinowitz directly beneficially owns 2,320,852 shares of Natera common stock and indirectly owns 15,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The sales were executed under pre-arranged Rule 10b5-1 trading plans, which are common for executives to manage personal finances and diversify holdings, mitigating the negative perception often associated with insider selling. The prices achieved are relatively high.

Positives

• The sales were executed at relatively high share prices, indicating favorable market conditions for the executive's personal financial planning.
• All reported transactions were conducted under pre-arranged Rule 10b5-1 trading plans, which demonstrates a structured approach to managing personal holdings and mitigates concerns about opportunistic insider selling.

Negatives

• The sale of a significant number of shares (49,990) by a key executive, even if pre-planned, could be perceived by some investors as a slight reduction in insider conviction or a move to diversify away from the company's stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning within the context of their compensation and holdings in a publicly traded biotechnology company.

Stakeholder Impact

• Shareholders: May interpret the insider selling, even if planned, with caution, though the existence of 10b5-1 plans generally reduces the perceived negative signal.

Key Dates

Recommendation

The reported transactions are sales of common stock by an executive, but they were executed under pre-arranged Rule 10b5-1 trading plans. Such plans are a common practice for executives to manage personal liquidity and diversify their portfolios, and they typically do not signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this filing. The prices achieved are relatively high, which could be seen as a positive for the executive, but the overall impact on investment sentiment is neutral to slightly negative, thus a 'hold' recommendation is appropriate.

Keywords

Natera, NTRA, Form 4, Insider Transaction, Stock Sale, Matthew Rabinowitz, Executive Chairman, 10b5-1 Plan